OKYO Pharma Limited (OKYO)
Nasdaq: OKYO · Biological Products, (No Diagnostic Substances) · London, GB · filing with the SEC since 2021
Who owns OKYO Pharma Limited
As filed with the SECHolders of 5% or more
4
Chernett Jorey holds 9.5% of Common, as its SCHEDULE 13G/A filed Feb 13, 2026 says.
Directors and officers
9
report now, of 10 people on the record since 2022. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Chernett Jorey
SCHEDULE 13G/A · filed Feb 13, 2026 · Common · 7.8% in Nov 14, 2025
Sirenia Capital Management LP
SCHEDULE 13G · filed May 15, 2026 · Ordinary Shares, without par value
Woodline Partners LP
SCHEDULE 13G · filed May 15, 2026 · Ordinary Shares, no par value
Laura Natalia Monica Fonda
SCHEDULE 13G · filed Oct 29, 2025 · Common
Dauntless Investment Group, LLC
SCHEDULE 13G/A · filed Feb 12, 2026 · Common · reported falling below 5%, from 6.3% in Nov 14, 2025
Point72 Asset Management, L.P.
SCHEDULE 13G/A · filed May 15, 2026 · Ordinary Shares, no par value · reported falling below 5%, from 7.9% in Feb 18, 2026
What OKYO reports owning in othersstakes of 5% or more, and other ties
OKYO Pharma Limited reports no stake in another company in the record.
Insider tradesForm 4
0sales
7purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$100,000bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window6 of 10 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Cerrone Gabriele M | Executive Chairman | 0 | $0 | 0 | 2 | $100,000 |
| Dempsey Robert John | CHIEF EXECUTIVE OFFICER | 0 | $0 | 0 | 1 | $0 |
| Jacob Gary S | CHIEF DEVELOPMENT OFFICER | 0 | $0 | 0 | 1 | $0 |
| Mantelli Flavio | CHIEF MEDICAL OFFICER | 0 | $0 | 0 | 1 | $0 |
| Patil Rajkumar V. | Chief Scientific Officer | 0 | $0 | 0 | 1 | $0 |
| Brancaccio John P | director | 0 | $0 | 0 | 1 | $0 |